Here’s what I find interesting about this survey:
Follow-on biologics are currently in the news big time, so it is probably no surprise that BIO members see this as a major issue. However, it and intellectual property protection should probably go hand-in-hand. The drug pricing and importation issue will probably become just that, a bigger issue if we go through any type of healthcare reform. There was a fair amount of news today about Congress debating cheaper imports. According to readers, stem cell research will continue to receive the most media attention in 2010. Probably because it is still considered controversial and controversy sells. There is no question that access to capital is the biggest issue facing the industry right now… but is it? According to Burrill & co., the industry raised nearly $18B this year compared to $10B last year. Partnering netted the industry more than $30B. So, with nearly $50B raised, 2009 will go down in history as the industry’s second largest financing year! (image source: Bio smartBrief)
UPDATE:
Cliff Cramer, Director of the Healthcare and Pharmaceutical Management Program at Columbia Business School, and a 25 year veteran of the healthcare industry, posted 4 predictions for 2010 at the Biotech Blog
. Among his predictions
Larger investments in emerging markets, notably China and India. Increasing use of IT by the healthcare industry – most likely in the form of PHRs and EMRs. Continued healthcare reform focusing on increased access, affordability and quality patient care. Continued consolidation, especially among pharmaceutical companies looking to fill empty pipelines and manage earnings before major near-term patent expirations.
No comments:
Post a Comment